A novel peptide encoded by circSRCAP confers resistance to enzalutamide by inhibiting the ubiquitin-dependent degradation of AR-V7 in castration-resistant prostate cancer

Abstract excerpt

BACKGROUND: The sustained activation of androgen receptor splice variant-7 (AR-V7) is a key factor in the resistance of castration-resistant prostate cancer (CRPC) to second-generation anti-androgens such as enzalutamide (ENZ). The AR/AR-V7 protein is regulated by the E3 ubiquitin ligase STUB1 and a complex involving HSP70, but the precise mechanism remains unclear. METHODS: High-throughput RNA sequencing was...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Circular RNAs in diseases
• Share to Prostate Cancer Diagnosis and Treatment
• Share to Prostate Cancer Treatment and Research